Zypadhera ® (olanzapin)

För fullständig produktresumé för Zypadhera® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

ZypAdhera® (olanzapinpamoat): Halveringstid och eliminering

Halveringstiden för olanzapin efter olanzapinpamoat är 30 dagar jämfört med 30 timmar efter oral administrering. Absorptionen och elimineringen är fullständig cirka sex till åtta månader efter den sista injektionen.

Label information

After a single intramuscular injection with olanzapine pamoate, the slow dissolution of the olanzapine pamoate salt in muscle tissue begins immediately and provides a slow continuous release of olanzapine for more than four weeks.1

The release becomes diminishingly smaller within eight to twelve weeks.1

The absorption and elimination are complete approximately six to eight months after the last injection.1

The combination of the release profile and the dosage regimen (intramuscular injection every two or four weeks) result in sustained olanzapine plasma concentrations. Plasma concentrations remain measurable for several months after each olanzapine pamoate injection.1

Olanzapine plasma clearance after oral olanzapine is lower in females (18.9 l/hr) versus males (27.3 l/hr), and in non-smokers (18.6 l/hr) versus smokers (27.7 l/hr). Similar pharmacokinetic differences between males and females and smokers and non-smokers were observed in olanzapine pamoate clinical trials. However, the magnitude of the impact of gender, or smoking on olanzapine clearance is small in comparison to the overall variability between individuals.1

For full information please refer to summary of product characteristics.

References

1. ZypAdhera [summary of product characteristics] Eli Lilly Netherland B.V., The Netherlands.

Datum fӧr senaste ӧversyn 2018 M04 12

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss